In an exclusive interview, Wockhardt Founder Chairman Dr. Habil Khorakiwala confirms a major transformation toward becoming a research-driven global biopharma pioneer. Following the breakthrough success and regulatory approvals for its novel antibiotic Zaynich, the company is pivoting its capital allocation strategy to aggressively fund its innovative R&D pipeline over the next three to five years. While global pharma giants scaled back antibiotic research due to weak economic returns, Wockhardt leveraged the lack of competition to target antimicrobial resistance, aiming to establish India as a premier innovation hub for global antibiotic discovery.